Skip to main content

Table 1 Baseline characteristics

From: Cancer survivors’ needs during various treatment phases after multimodal treatment for colon cancer - is there a role for eHealth?

Study number Gender Age at operation (ranges in years) Comorbiditiy Operation Postoperative complications Age at focus group (years) Time after operation (months) Time after last course of CTx (months) 8 courses of CTx received Stoma
FG1-R1 Male 65–70 Yes Laparascopic No 65–70 10 5 No No
FG1-R2 Female 40–45 No Open procedure No 40–45 14 6 Yes, with adjusted dose Yes
FG1-R3 Male NA No Conversion to open Yes 75–80 NA 4 Yes, with adjusted dose No
FG1-R4 Female 60–65 Yes Laparascopic No 60–65 17 11 Yes, with adjusted dose No
FG1-R5 Female 60–65 Yes Laparascopic No 60–65 17 10 Yes, with adjusted dose No
FG1-R6 Male NA No Laparascopic No 70–75 NA 11 Yes, with adjusted dose No
FG1-R7 Male 65–70 Yes Laparascopic No 65–70 16 11 No Yes
FG1-R8 Male 60–65 No Laparascopic No 60–65 16 12 Yes, with adjusted dose No
FG1-R9 Male 70–75 Yes Open procedure Yes 70–75 12 4 Yes, with adjusted dose No
FG1-R10 Male 60–65 Yes Laparascopic No 60–65 11 4 Yes No
FG1-R11 Female 30–35 No Conversion to open Yes 30–35 22 15 Yes, with adjusted dose No
FG2-R1 Female 75–80 Yes Laparascopic No 75–80 8 2 Yes No
FG2-R2 Female 50–55 Yes Laparascopic No 55–60 14 10 No No
FG2-R3 Male 65–70 No Laparascopic Yes 65–70 16 9 Yes No
FG2-R4 Male 50–55 Yes Laparascopic No 50–55 14 8 Yes, with adjusted dose No
FG2-R5 Male 55–60 Yes Open procedure No 55–60 11 4 No Yes
FG2-R6 Female 55–60 No Laparascopic No 55–60 12 6 Yes, with adjusted dose No
FG2-R7 Female 65–70 Yes Laparascopic No 65–70 20 12 No No
FG2-R8 Female 65–70 Yes Laparascopic No 65–70 22 15 Yes, with adjusted dose No
FG2-R9 Male 60–65 Yes Laparascopic No 65–60 20 17 No No
FG2-R10 Female 55–60 No Laparascopic No 55–60 15 9 Yes, with adjusted dose No
FG2-R11 Female 70–75 No Open procedure Yes 70–75 15 8 Yes Yes
  1. FG1 Focus group discussion 1, FG2 Focus group discussion 2, R Respondent number
\